ArticleThrombosis research2016
Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study.
Article in Thrombosis research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Pharmacoeconomic evaluation of direct oral anticoagulants for cancer-associated thrombosis: a systematic review.Frontiers in public health · 2025Pooled it
- Neutrophil extracellular traps in thrombosis of hematologic malignancies: Underlying mechanisms and therapeutic opportunities (Review).International journal of molecular medicine · 2026Review
- Development and External Validation of a Postoperative Risk Score for Venous Thromboembolism in Epithelial Ovarian Cancer.The Kaohsiung journal of medical sciences · 2026Article
- Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event.Frontiers in oncology · 2026Article
- Thromboembolic Risks in Pancreatic Ductal Adenocarcinoma: A Review of Anatomical and Clinical Variations.Canadian journal of gastroenterology & hepatology · 2026Review
- Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab.Discover medicine · 2026Article
- Incidence and risk factors of venous and arterial thromboembolism events in lung cancer patients treated with immune checkpoint inhibitors.Frontiers in pharmacology · 2026Article
- Article
- Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study.The oncologist · 2025Observational
- Factors associated with thrombosis among solid organ cancer patients in Kuala Lumpur, Malaysia.Thrombosis journal · 2025Article
- A nomogram predicting venous thromboembolism risk in primary liver cancer patients.Journal of thrombosis and thrombolysis · 2025Article
- Cancer progression and tumor hypercoagulability: a platelet perspective.Journal of thrombosis and thrombolysis · 2024Review
- Trends and Updates on the Epidemiology of Cancer Associated Thrombosis: A Systematic Review.Bleeding, thrombosis and vascular biology · 2024Article
- Risk factors for peripherally inserted central catheter-related venous thrombosis in adult patients with cancer.Thrombosis journal · 2024Article
- Incidence of and risk factors for venous thrombosis in hospitalized patients with hematologic malignancies: A single-center, prospective cohort study.Northern clinics of Istanbul · 2024Article
- In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery.Annals of surgical oncology · 2023Article
- Acute and chronic venous occlusion.The British journal of radiology · 2023Review
- Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.JAMA network open · 2023Article
- Risk factors for totally implantable access ports-associated thrombosis in pediatric oncology patients.Scientific reports · 2023Article
- Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.Acta Cardiologica Sinica · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIndependent risk factors for cancer-associated incident venous thromboembolism (VTE) and their magnitude of risk are not fully characterized.
aimTo identify non-cancer and cancer-specific risk factors for cancer-associated incident VTE.
methodsIn a population-based retrospective case-control study, we used Rochester Epidemiology Project and Mayo Clinic Cancer Registry resources to identify all Olmsted County, MN residents with active cancer-associated incident VTE, 1973-2000 (cases; n=570) and 1-3 residents with active cancer matched to each case on age, sex, date and duration of active cancer (controls; n=604). Using conditional logistic regression, we tested cancer and non-cancer characteristics for an association with VTE, including a cancer site VTE risk score.
resultsIn the multivariable model, higher cancer site VTE risk score (OR=1.4 per 2-fold increase), cancer stage≥2 (OR=2.2), liver metastasis (OR=2.7), chemotherapy (OR=1.8) and progesterone use (OR=2.1) were independently associated with VTE, as were BMI<18.5kg/m(2) (OR=1.9) or ≥35kg/m(2) (OR=4.0), hospitalization (OR=7.9), nursing home confinement (OR=4.7), central venous (CV) catheter (OR=8.5) and any recent infection (OR=1.7). In a subgroup analysis, platelet count≥350×10(9)/L at time of cancer diagnosis was marginally associated with VTE (OR=2.3, p=0.07).
conclusionCancer site, cancer stage≥2, liver metastasis, chemotherapy, progesterone, being underweight or obese, hospitalization/nursing home confinement, CV catheter, and infection are independent risk factors for incident VTE in active cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.